What does the Brexit effect mean for UK patient access?
Remap Consulting, joined by Paul Miller of NICE, will be reviewing the regulatory and market access impacts of Brexit on a manufacturer’s European launch sequence and will summarise the recent changes at NICE.
The panel will aim to answer these two questions:
• Will it be worth the trouble launching in the UK in five years’ time?
• Should the UK be deprioritised in the launch sequence?